India, Aug. 29 -- The Maharashtra Food and Drug Administration (FDA) on Saturday withdrew its order to cancel the drug sale licence of Cipla Pharma & Life Sciences Limited's Pune unit after the Bombay high court rapped the state regulator for going "overboard" and behaving in a "high-handed" manner.

The FDA had cancelled the drug sale licenses of Cipla's carrying and forwarding facility at Wadki in Pune for serious irregularities related to the packaging, storage and recall of Reactin Plus Tablets, with effect from August 27.

A bench of acting Chief Justice Ravindra Ghuge and Justice Gautam Ankhad said the FDA has acted against the "principles of natural justice". The observation came after Cipla said on Friday that it had challenged th...